Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment

References

1. ↵
   1. World Health Organization. Epilepsy factsheet No. 999

   (2015) (WHO, Geneva (CH)) Available at: http://www.who.int/mediacentre/factsheets/fs999/en/. Accessed 6th January 2016.
2. ↵
   1. Khatri IA,
   2. Iannaccone ST,
   3. Ilyas MS,
   4. Abdullah M,
   5. Saleem S

   (2003) Epidemiology of Epilepsy in Pakistan:a review of the literature. J Pak Med Assoc 53, 594–597.
3. ↵
   1. Kullo IJ,
   2. Ballantyne CM

   (2005) Conditional risk factors for atherosclerosis. Mayo Clin Proc 80, 219–230.
4. ↵
   1. Tan TY,
   2. Lu CH,
   3. Chuang HY,
   4. Lin TK,
   5. Liou CW,
   6. Chang WN,
   7. et al.

   (2009) Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 50, 1579–1586.
5. ↵
   1. Lopinto-Khoury C,
   2. Mintzer S

   (2010) Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol 12, 300–308.
6. ↵
   1. Mehrpour M,
   2. Zamani B,
   3. Abbasi M,
   4. Shojaie M,
   5. Gharibzadeh S

   (2014) Atherogenic consequence of antiepileptic drugs:a study of intima-media thickness. Neurol Sci 35, 253–257.
7. ↵
   1. Chaung YC,
   2. Chaung HY,
   3. Lin TK,
   4. Chang CC,
   5. Lu CH,
   6. Chang WN,
   7. et al.

   (2012) Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 53, 120–128.
8. ↵
   1. Nikolaos T,
   2. Stylianos G,
   3. Chryssoula N,
   4. Irini P,
   5. Christos M,
   6. Dimitrios T,
   7. et al.

   (2004) The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 10, MT50–MT52.
9. ↵
   1. Abaci A,
   2. Saygi M,
   3. Yis U,
   4. Demir K,
   5. Dirik E,
   6. Bober E

   (2009) Metabolic alterations during valproic acid treatment:a prospective study. Pediatr Neurol 41, 435–439.
10. ↵
    1. Grosso S,
    2. Mostardini R,
    3. Piccini B,
    4. Balestri P

    (2009) Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother 43, 45–50.
11. ↵
    1. Ben-Menachem E

    (2007) Weight issues for people with epilepsy--a review. Epilepsia 48, 42–45.
12. ↵
    1. Gaspari CN,
    2. Guerreiro CA

    (2010) Modification in body weight associated with antiepileptic drugs. Arquivos de neuro-psiquiatria 68, 277–281.
13. ↵
    1. Pickrell WO,
    2. Lacey AS,
    3. Thomas RH,
    4. Smith PE,
    5. Rees MI

    (2013) Weight change associated with antiepileptic drugs. J Neurol Neurosurg Psychiatry 84, 796–799.
14. ↵
    1. Hogan RE,
    2. Bertrand ME,
    3. Deaton RL,
    4. Sommerville KW

    (2000) Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res 41, 23–28.
15. ↵
    1. Devinsky O,
    2. Vuong A,
    3. Hammer A,
    4. Barrett PS

    (2000) Stable weight during lamotrigine therapy:a review of 32 studies. Neurology 54, 973–975.
16. ↵
    1. Sonmez FM,
    2. Demir E,
    3. Orem A,
    4. Yildirmis S,
    5. Orhan F,
    6. Aslan A,
    7. et al.

    (2006) Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol 21, 70–74.
17. ↵
    1. Tomoum HY,
    2. Awadallah MM,
    3. Fouad DA,
    4. Ali AH

    (2008) Lipid profile, apolipoproteins A and B in children with epilepsy. J Child Neurol 23, 1275–1281.
18. ↵
    1. Stocker R,
    2. Keaney JF Jr.

    (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84, 1381–1478.
19. ↵
    1. Mintzer S,
    2. Mattson RT

    (2009) Should enzyme-inducing antiepileptic drugs be considered first-line agents? Epilepsia 50, 42–50.
20. ↵
    1. Svalheim S,
    2. Luef G,
    3. Rauchenzauner M,
    4. Morkrid L,
    5. Gjerstad L,
    6. et al.

    (2010) Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. Acta Neurol Scand Suppl 190, 30–33.
21. ↵
    1. Pachachi OA,
    2. Thanoon IA

    (2011) Body mass index and some biochemical parameters among valproate treated male epileptic patients. Ann Coll Med Mosul 37, 114–121.
22. ↵
    1. Kim JY,
    2. Lee HW

    (2007) Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 48, 1336–1370.
23. ↵
    1. Demircioglu S,
    2. Soylu A,
    3. Dirik E

    (2000) Carbamazepine and valproic acid:effects on the serum lipids and liver functions in children. Pediatr Neurol 23, 142–146.
24. ↵
    1. Verrotti A,
    2. Manco R,
    3. Agostinelli S,
    4. Coppola G,
    5. Chiarelli F

    (2010) The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 51, 268–273.
25. ↵
    1. Arida RM,
    2. de Almeida ACG,
    3. Cavalheiro EA,
    4. Scorza FA

    (2013) Experimental and clinical findings from physical exercise as complementary therapy for epilepsy. Epilepsy Behav 26, 273–278.
26. ↵
    1. Khot SS,
    2. Shaikh H,
    3. Lalitkumar G

    (2013) Atherosclerotic risk among Epileptic patients taking Carbamazepine, Phenytoin treatment:A Brief Review. Int J Pharm Sci Res 4, 900–906.